SLS
NASDAQ HealthcareSELLAS Life Sciences Group, Inc. - Common Stock
Biotechnology
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
�� 市场数据
| 价格 | $8.33 |
|---|---|
| 成交量 | 10,153,906 |
| 市值 | 1.55B |
| 贝塔系数 | 2.240 |
| RSI（14日） | 68.1 |
| 200日均线 | $3.53 |
| 50日均线 | $5.73 |
| 52周最高 | $9.51 |
| 52周最低 | $1.39 |
| Forward P/E | -55.53 |
| Price / Book | 14.07 |
🎯 投资策略评分
SLS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (91/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🔪 Falling Knife (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SLS in your text
粘贴任何文章、记录或帖子 — 工具将提取 SLS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.